SCHEMBL3492965

SCHEMBL3492965

COC(=O)c1ccc2occ(-c3ccc(OC)cc3)c2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 5/20 0.62
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
NPC1 O15118 4/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
CYP2D6 P10635 3/20 0.50
CYP2C9 P11712 3/20 0.50
CYP2C19 P33261 3/20 0.50
KDM4E B2RXH2 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 2/20 0.50
NQO2 P16083 1/20 0.50
TP53 P04637 1/20 0.50
CYP3A4 P08684 1/20 0.50
BCL2 P10415 1/20 0.50
HPGD P15428 1/20 0.50
MAOA P21397 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3493518 0.88 GSK3B (0.57) GSK3BNPC1POLBNQO2MAOB
SCHEMBL12365259 0.86 GSK3B (0.61) GSK3BNPC1POLBMAPTSMN1; SMN2
SCHEMBL3490849 0.86 CA1 (0.55) GSK3BCA1CA2NPC1POLB
SCHEMBL3493195 0.85 GSK3B (0.51) GSK3BNPC1POLBMAPTSMN1; SMN2
SCHEMBL3491084 0.85 GSK3B (0.60) GSK3BNPC1POLBMAPTSMN1; SMN2
SCHEMBL3492564 0.83 GSK3B (0.57) GSK3BCA1CA2NPC1POLB
SCHEMBL14852229 0.79 GSK3B (0.53) GSK3BNPC1POLBALDH1A1NQO2
SCHEMBL3493916 0.77 GSK3B (0.52) GSK3BNPC1POLBMAPTSMN1; SMN2
SCHEMBL3493911 0.77 GSK3B (0.49) GSK3BNPC1POLBMAPTSMN1; SMN2
SCHEMBL6701016 0.77 CA1 (0.65) CA1CA2NPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492378-B2 GSK-3β inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-23 US disclosed
US-20100069381-A1 GSK-3BETAINHIBITOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069381-A1 GSK-3BETAINHIBITOR GSK3B, GSK3A, GSKIP GSK3B 1/4885CA1 730/4885CA2 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.